Public Funding of Clinical-Stage Antibiotic Development in the United States and European Union
| Autor: | Michael J. Eichberg |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Financing
Government Economic growth Biomedical Research Health (social science) National security Health Toxicology and Mutagenesis Management Monitoring Policy and Law Intellectual property Technology Transfer Antibiotic resistance Environmental health Drug Discovery Humans media_common.cataloged_instance European Union European union IP address management Health policy media_common Government business.industry Health Policy Corporate governance Public Health Environmental and Occupational Health Original Articles Intellectual Property United States Anti-Bacterial Agents Government Programs Emergency Medicine United States Dept. of Health and Human Services Business Safety Research |
| Zdroj: | Health Security. 13:156-165 |
| ISSN: | 2326-5108 2326-5094 |
| Popis: | The health and national security challenge of antibiotic resistance has led governments to adopt policies to stimulate new antibiotic R&D. Government programs that directly fund late-stage clinical development of antibiotics have emerged, including the Broad Spectrum Antimicrobial Program of the Biomedical Advanced Research and Development Authority in the United States, and the New Drugs for Bad Bugs program of the Innovative Medicines Initiative in the European Union. These efforts are collectively investing nearly $1 billion and are supporting nearly 20% of the global antibiotic pipeline. This article describes these programs, including the antibiotics and their targeted pathogens and clinical indications, as well as program mechanisms for project eligibility, selection, governance, funding, and IP management. Preliminary assessment of the impact of these mechanisms on the success of the programs is provided. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|